Warning

This presentation and its content may not be distributed, published or reproduced, in whole or in part, or disclosed by recipients directly or indirectly to any other person. Any breach of these restrictions may constitute a violation of applicable laws. Consequently, anyone in possession of this presentation must inform themselves and respect these restrictions. This presentation may include statements which may constitute forward-looking statements. All statements that deal with expectations or projections regarding the future, including, but not limited to, statements about growth strategy, business development, market position, expenses and financial results, are forward-looking statements. The peak sales forecast / potential in the presentation represents the potential sales of the product (s) to the marketing partner. Forward-looking statements are based on certain assumptions and expectations of future events. This presentation should not be construed as a recommendation or forecast by Sun Pharma Advanced Research Company Limited (“Company”). Please note that the past performance of the Company is not and should not be taken as indicative of future results. The Company cannot guarantee that these assumptions and expectations are correct or will be achieved. Actual results, performance or achievements could therefore differ materially from those projected in these forward-looking statements. The Company does not undertake to revise any forward-looking statements that may be made from time to time by or on behalf of the Company. In light of these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements.

The information contained in these documents has not been independently verified. None of the Company, its directors, promoters or affiliates, nor any of its respective employees, advisers or representatives or any other person accepts any liability whatsoever, whether tort, contractual or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred in any way resulting, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representations or warranties, express or implied, for the contents of this document, including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of between them, or on their behalf, and nothing in this presentation should be taken as a promise or representation in this regard, whether as to the past or the future. The information and opinions contained in this presentation are current, and unless otherwise indicated, as of the date of this presentation. The Company assumes no obligation to update or revise any information or opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinion or information expressed in this presentation is subject to change without notice. This presentation does not constitute or form part of any offer, invitation or inducement to sell or issue, nor any solicitation of an offer to purchase or subscribe for securities of the Company, nor the latter or any part of it. this or the fact of its distribution constitutes the basis of, or may be relied upon in connection with, any contract or commitment in this regard. No person is authorized to give any information or make any statement not contained or inconsistent with this presentation and if given or made, such information or statements should not be considered to have been authorized by any person. By participating in this presentation or accepting any copies of the slides presented, you agree to be bound by the foregoing limitations. All brand names and trademarks are the property of their respective owners.

SPARC – Review of our journey

4 clinical stage programs targeting areas of high unmet need

Targeting large addressable patient populations with a combined maximum sales potential of $ 20 billion or more in 6 indications in oncology, neurology and immunology

Discovery and development through validated and novel biology to balance risk

Multimodal portfolio covering small and large molecules and conjugated entities

More than 10 preclinical programs, including a TAA-1 program, which should enter clinical practice in 2023

Proven high-quality R&D organization with global operations with high return on capital

More than 350 scientists in 4 research centers, including the United States; $ 400M invested to date 2 USFDA approvals for internally developed assets

3 NDAs targeted for submission in 2022

Very flexible model to maximize shareholder value

Partnerships to maximize significant business potential and provide non-dilutive capital

Maximize the multi-TA opportunity and preserve the optionality for spin-offs

Experienced management team and globally recognized scientific advisory board

ADC = Drug Antibody Conjugate | TA = Therapeutic Area | USFDA = United States Food and Drug Administration | NDA = Approval of a new drug | TAA-1 = antigen associated with tumor-1